410results about "Hormone peptides" patented technology

To provide an adiponectin enhancer and an oral composition for enhancing adiponectin, having the effect of enhancing adiponectin.SOLUTION: An adiponectin enhancer comprises plasmalogen as an active ingredient.SELECTED DRAWING: Figure 1

The invention relates to the technical field of biological medicine, in particular to eye drops containing recombinant protein as well as a preparation method and application of the eye drops. Comprising the following components: 0.01%-1% of recombinant human TFF3 protein, 0.1%-1% of an osmotic pressure regulator, 0.08%-2% of a pH regulator, 0.05%-0.15% of a thickening agent, 0.01%-0.1% of a surfactant, 0.01%-0.1% of a protective agent and the balance of water for injection, the traditional Chinese medicine composition can be used for treating the xerophthalmia, can promote wound healing and cell migration, has the effects of inhibiting inflammation and cell apoptosis, and can act on a plurality of target spots at the same time, so that the tear film stability is improved, ocular surface inflammation is inhibited, the vicious circle of the xerophthalmia is broken, and the xerophthalmia is treated more comprehensively and effectively; the problems that in the prior art, xerophthalmia medicine targets are single, and xerophthalmia cannot be comprehensively and effectively treated are solved.

The invention provides a human amylin polypeptide analogue containing non-natural amino acid and application of a derivative of the human amylin polypeptide analogue to treatment of obesity and diabetes related diseases. The human amylin polypeptide derivative obtained by introducing non-natural amino acid into the N terminal of human amylin and modifying by albumin binding residues can effectively prevent enzymatic degradation, prolong the half-life period, participate in delay of gastric emptying and inhibition of postprandial glucagon release, can influence the rising speed of postprandial blood sugar through various mechanisms, and can be used for preparing the anti-hyperglycemia human amylin polypeptide derivative. The compound can be used for preventing or treating obesity, excessive ingestion, diabetes mellitus and other related metabolic diseases.

The invention discloses an SmCLE mature peptide and application thereof in plant stress resistance, and belongs to the technical field of plant biology. According to the technical scheme, the SmCLE mature peptide is provided, and the amino acid sequence of the SmCLE mature peptide is SEQ ID NO: 1. The CLE peptide is applied to the aspect of plant stress resistance, the problem that an existing CLE peptide cannot be applied to stress resistance of plants, especially medicinal plants or non-mode crops is solved, the CLE peptide has high biocompatibility and targeting performance, and the biomass and yield of the crops in a stress environment can be remarkably improved.

The invention relates to the technical field of biological medicine, and discloses an intestinal insulinotropic analogue with multiple biological activities, a synthesis method, a pharmaceutical composition and application, the synthesized intestinal insulinotropic analogue has triple agonist activity of a GLP-1 receptor, a glucagon receptor and a CCK-1 receptor, not only has the treatment effect of GLP-1 on diabetes, but also has the treatment effect of GLP-1 on CCK-1, and also has the effect of GLP-1 on CCK-1 on CCK-1. The traditional Chinese medicine composition also has the regulating effect of glucagon on lipolysis and energy metabolism and the beneficial effect of CCK on appetite inhibition, so that a synergistic effect is generated on sugar, fat and energy metabolism; the application has great potential in preparation of drugs for treating metabolic syndromes, such as diabetes, obesity, non-alcoholic fatty liver diseases, dyslipidemia and other diseases.

To provide a pharmaceutical GIP / GLP1 co-agonist peptide composition for subcutaneous injection.SOLUTION: A pharmaceutical composition for treating diabetes comprises: tirzepatide, or a pharmaceutically acceptable salt thereof; an agent selected from the group consisting of NaCl and propylene glycol; and dibasic sodium phosphate.SELECTED DRAWING: None

The present disclosure describes a GnRH therapeutic agent for neutralizing GnRH levels in a subject, which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and / or metastasis. The therapeutic agent is synthetically produced. The GnRH therapeutic agent includes a hapten carrier (hC) comprising a monomeric peptide (MP) synthesized separately from the GnRH peptide. After self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate that can serve as a therapeutic agent. The MP comprises heptad repeats following a specific pattern. The hC can comprise a GnRH peptide bound to the monomeric peptide prior to self-assembly to form a therapeutic agent. Optionally, the GnRH-hC conjugate further comprises one or more T cell epitopes at the N- and / or C-termini of one or more amphipathic alpha helices. The present disclosure also describes compositions, including immunogenic compositions, comprising the therapeutic agents described herein.

The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.

The disclosure provides compositions and methods for the treatment and / or prevention of sickle cell disease.

The present invention relates to the use of petrelintide to reduce body fat or inhibit gain of body fat whilst preserving lean mass.

The present invention provides an antibody pair that binds human mature prolactin, comprising: a monoclonal antibody 1 or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin, and a monoclonal antibody 2 or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin. The present invention also provides use of the antibody pair of the present invention in manufacturing a kit for measuring prolactin in a biological sample. The present invention also provides a monoclonal antibody or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin and a monoclonal antibody or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin, respectively. The present invention also provides a method for measuring prolactin in a biological sample using the antibody pair of the present invention. The present invention also provides a method for producing a monoclonal antibody in the antibody pair of the present invention.

The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.

The invention relates to the field of biological medicine preparation, in particular to a semi-synthesis preparation method of canagliflozin, which comprises the following steps: (1) under the condition that the pH value is 9.0-11.5, carrying out selective protection on lysine epsilon amino of a canagliflozin intermediate 36AA to obtain Boc-protected 36 peptide (BoC-36AA); (2) under the condition that the pH (Potential of Hydrogen) is 8.5 to 9.0, carrying out a reaction on side chain Glu-eicosandioic acid and the lysine alpha-amino group of the Boc-36AA to obtain 36-AA (SC-36AA) with a side chain; (3) carrying out a reaction on the SC-36AA and prolinamide, so as to obtain a canagliflozin precursor; and (4) cracking the canagliflozin precursor to obtain the canagliflozin. The preparation method is simple to operate, low in cost, high in yield and high in purity, the total reaction yield is more than 56%, and the HPLC (high performance liquid chromatography) purity is more than or equal to 99.6%.

Hybrid peptide compounds having a modified lysine residue are described herein.

To develop a more efficient and cost-effective method to produce therapeutics for treating prostate cancer.SOLUTION: Provided is a GnRH therapeutic for neutralizing GnRH levels in a subject, which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and / or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic comprises a hapten carrier (hC) including a monomeric peptide (MP) synthesized separately from the GnRH peptide, and after self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate that can serve as a therapeutic. The MP includes heptad repeats following a specific pattern. The hC may include a GnRH peptide attached to a monomeric peptide prior to self-assembly to form a therapeutic. Optionally, the GnRH-hC conjugate further comprises one or more T cell epitopes at the N- and / or C-terminus of one or more amphipathic alpha-helices. Also provided are compositions including immunogenic compositions comprising the therapeutic.SELECTED DRAWING: None

The technology described herein is directed to probiotic microbes engineered to secrete at least one enteroendocrine modulating polypeptide, which can be a sweet protein. In some embodiments, the probiotic microbe secretes the enteroendocrine modulating polypeptide in the distal colon. Also described herein are nucleic acids or vectors comprising a coding sequence for the enteroendocrine modulating polypeptide. Also described herein are compositions comprising the engineered probiotic microbe. Methods of using such probiotic microbes and compositions are also disclosed, including methods for modulating enteroendocrine cells and methods for treating metabolic diseases.

The invention discloses a preparation method of Retatrutide, and belongs to the technical field of polypeptide synthesis. The invention relates to a preparation method of Retatrutide, which comprises the following steps: by taking Sieber amide resin as a coupling resin carrier, sequentially coupling and inoculating Fmoc protected amino acid and dipeptide and tripeptide protected amino acid fragments, and then cutting the resin to prepare a peptide fragment I, namely an intermediate M1; cTC resin is used as a coupling resin carrier, Fmoc protected amino acid and oligopeptide protected amino acid fragments are sequentially coupled and connected, then the resin is cut, and a peptide fragment II, namely an intermediate M2, is prepared; coupling the intermediate M1 and the intermediate M2 to prepare full-protection Retatrutide, namely an intermediate M3, and cracking the intermediate M3 by using a cracking agent to remove a protective functional group, so as to obtain a crude Retatrutide product; and dissolving, filtering, purifying, and freeze-drying to obtain a Retatrutide refined product. Two long peptide fragments and a plurality of protected amino acid fragments are used for preparing Retatrutide, the generation of impurities is reduced, the single impurity is small, the purification difficulty is reduced, the product purity is ensured, and the purity of the obtained product is greater than 98.0%.

The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their HbA1c goal using GLP-1 RA treatment. The present invention provides a method for improving weight management in a patient in need thereof, comprising administering to said patient tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their weight management goal using GLP-1 RA treatment.

The preparation method comprises the following steps: according to an Fmoc solid-phase synthesis method, adopting Sieber resin as a solid-phase synthesis carrier, and sequentially coupling to obtain full-protection peptide resin; cutting the fully-protected peptide resin by using a DCM solution of TFA with a volume fraction of 3-5%, filtering to remove waste resin, and concentrating the obtained filtrate into a viscous solid; and adding a cracking reagent into the viscous solid, carrying out cracking, adding an ether solvent after the cracking is finished, carrying out sedimentation, and filtering and drying a precipitate to obtain a crude product of the tilpotide. By adopting the method disclosed by the invention, the use amount of TFA can be reduced by 70%, the use amount of ether as a required settling solvent is also reduced by 90%, precipitated particles are easily filtered by using filter cloth or filter paper, the limitation of the volume of a settling kettle on cracking batches is solved, the problem of solid-liquid separation of settling liquid is solved, the production efficiency is greatly improved, and the production cost is reduced.

Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent are described herein.

Provided are CRF2 receptor agonists as defined by Chemical Formulas 1 and 2 and fatty acid conjugates thereof.

To provide a method for generating oligocortical spheroids (OCS) from pluripotent stem cells (PSC).SOLUTION: A method comprises the steps for: a) generating a neurocortical spheroid (NCS) through neurocortical patterning of pluripotent stem cells; b) subjecting the neurocortical spheroid to timed exposure to defined oligodendrocyte lineage growth factors and / or hormones, to promote proliferation, survival and / or expansion of native oligodendrocyte progenitor cell (OPC) populations within the neurocortical spheroid, thereby generating the oligocortical spheroid, wherein the oligocortical spheroid contains oligodendrocyte progenitor cells capable of differentiating into myelinating oligodendrocytes (ODCs) that are capable of myelinating axons.SELECTED DRAWING: Figure 1-1

The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants thereof and b) a second peptide with agonist activity of OR1 and OR2 receptors or functional fragments or derivatives, or biologically active variants thereof.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

The present invention relates to the fields of molecular biology, virology, immunology and medicine, and in particular to a preparation method for a castrating AP205 virus-like particle subunit vaccine.

Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to human Fc gamma receptor IIIA (FcγRIIIA) compared to naturally occurring antibodies and retain good manufacturability. Such heterodimeric proteins are particularly useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for producing these heterodimeric proteins.

The present disclosure relates to antibody molecules that bind to epidermal growth factor receptor (EGFR) and / or c-Met, and conjugates containing these antibody molecules. The antibody molecules and conjugates have application, for example, in the treatment of cancer.

Polypeptides that are pramlintide analogs and uses thereof are disclosed. In particular, the present invention relates to polypeptides of SEQ ID NO: 2 that are pramlintide analogs conjugated to a half-life extending moiety, such as an albumin binding moiety, and uses thereof.

Novel kisspeptin-13 or KP-13 peptides and KP-13 satellites or modified peptides (KPSATs) are disclosed having improved therapeutic benefits in regulating pathophysiological changes in various tissues, particularly lung tissue. These KPSATs have improved antiproliferative effects and non-cytotoxic effects on airway smooth muscle cells and tissue.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.